This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
Effects of general practitioner training and family support services on the care of home-dwelling dementia patients–results of a controlled cluster-randomized study
Donath, Carolin,
Grässel, Elmar,
Grossfeld-Schmitz, Maria,
Menn, Petra,
Lauterberg, Jörg,
Wunder, Sonja,
Marx, Peter,
Ruckdäschel, Stephan,
Mehlig, Hilmar,
Holle, Rolf
Background: More than 90% of dementia patients are cared for by their general practitioners, who are decisively involved in the diagnosis, therapy and recommendation of support services.; Objective: To test whether special training of general practitioners alters the care of dementia patients through their systematic recommendation of caregiver counseling and support groups.; Method: 129 general […]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
Dombrovski, Alexandre Y.,
Mulsant, Benoit H.,
Ferrell, Robert E.,
Lotrich, Francis E.,
Rosen, Jules I.,
Wallace, Meredith,
Houck, Patricia R.,
Mazumdar, Sati,
Pollock, Bruce G.
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]
Low-dose divalproex in agitated patients with Alzheimer’s disease
Adequate treatment of behavioral disturbances in Alzheimer’s disease is both important and difficult. This report describes a case series that examined the effectiveness and safety of low-dose divalproex in the treatment of agitated patients with Alzheimer’s disease who were admitted to an inpatient geriatric psychiatry unit over a 1-year period. All patients had agitation due […]
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer’s disease
Boche, Delphine,
Donald, Jane,
Love, Seth,
Harris, Scott,
Neal, James W.,
Holmes, Clive,
Nicoll, James A. R.
Alzheimer’s disease (AD) pathology is characterised by aggregation in the brain of amyloid-beta (Abeta) peptide and hyperphosphorylated tau (phospho-tau), although how these proteins interact in disease pathogenesis is unclear. Abeta immunisation results in removal of Abeta from the brain but cognitive decline continues to progress, possibly due to persistent phospho-tau. We quantified phospho-tau and Abeta42 […]
A single ascending dose study of bapineuzumab in patients with Alzheimer disease
Black, Ronald S.,
Sperling, Reisa A.,
Safirstein, Beth,
Motter, Ruth N.,
Pallay, Allan,
Nichols, Alice,
Grundman, Michael
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. Thirty patients received bapineuzumab infusion of 0.5, 1.5, or 5 mg/kg or placebo (6 active, 2 placebo for 0.5 […]
3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
Apostolova, Liana G.,
Thompson, Paul M.,
Green, Amity E.,
Hwang, Kristy S.,
Zoumalan, Charleen,
Jack, Clifford R., Jr.,
Harvey, Danielle J.,
Petersen, Ronald C.,
Thal, Leon J.,
Aisen, Paul S,
Toga, Arthur W.,
Cummings, Jeffrey L.,
Decarli, Charles S.
We applied the hippocampal radial atrophy mapping technique to the baseline and follow-up magnetic resonance image data of 169 amnestic mild cognitive impairment (MCI) participants in the imaging arm of the Alzheimer’s Disease Cooperative Study MCI Donepezil/Vitamin E trial. Sixty percent of the subjects with none to mild hippocampal atrophy rated with the visual medial […]
A practice-based intervention to improve primary care for falls, urinary incontinence, and dementia
Wenger, Neil S.,
Roth, Carol P.,
Shekelle, Paul G.,
Young, Roy T.,
Solomon, David H.,
Kamberg, Caren J.,
Chang, John T.,
Louie, Rachel,
Higashi, Takahiro,
MacLean, Catherine H.,
Adams, John,
Min, Lillian C.,
Ransohoff, Kurt,
Hoffing, Marc,
Reuben, David B.
Objectives: To determine whether a practice-based intervention can improve care for falls, urinary incontinence, and cognitive impairment.; Design: Controlled trial.; Setting: Two community medical groups.; Participants: Community-dwelling patients (357 at intervention sites and 287 at control sites) aged 75 and older identified as having difficulty with falls, incontinence, or cognitive impairment.; Intervention: Intervention and control […]
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
Wang, Lucy Y.,
Shofer, Jane B.,
Rohde, Kirsten,
Hart, Kim L.,
Hoff, David J.,
McFall, Yun H.,
Raskind, Murray A.,
Peskind, Elaine R.
Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]